Clinical Trial Participation

We expect to commence a Phase 3 trial of RT-100 AC6 gene transfer for patients with heart failure and reduced left ventricular ejection fraction in the second half of 2017, across 60 medical centers in the United States. Additional details on the clinical trial – including patient enrollment information – will be available soon.

We will provide updates on future clinical trials of all of our gene and peptide therapy candidates as they become available.

Explore More